Therapeutic insights from genomic studies of head and neck squamous cell carcinomas

Cancer Discovery

Volumn 5, Issue 3, 2015, Pages 239-244

  Hammerman, Peter S ^a,b   Neil Hayes, D ^c   Grandis, Jennifer R ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CETUXIMAB; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IPILIMUMAB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; BIOLOGICAL MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COPY NUMBER VARIATION; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC MARKER; GENOMICS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE EVASION; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; ONCOGENE RAS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; WART VIRUS; WNT SIGNALING PATHWAY; CARCINOMA, SQUAMOUS CELL; COMPLICATION; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOTHERAPY; METABOLISM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PROCEDURES; VIROLOGY;

BIOMARKERS; CARCINOMA, SQUAMOUS CELL; GENOMICS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84925296349     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1205     Document Type: Article

References (36)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184–94.
2. Ang KK, Chen A, Curran WJ Jr, Garden AS, Harari PM, Murphy B A, et al. Head and neck carcinoma in the United States: fi rst comprehensive report of the longitudinal oncology registry of head and neck carcinoma (LORHAN). Cancer 2012;118:5783–92.
3. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–4.
4. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensa-doun RJ, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26: 5518–23.
5. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan P F, et al. Human papillomavirus and survival of patients with oropharyn-geal cancer. N Engl J Med 2010;363:24–35.
6. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294–301.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–78.
8. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170–6.
9. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2659–65.
10. Vokes EE, Seiwert TY. EGFR-directed treatments in SCCHN. Lancet Oncol 2013;14:672–3.
11. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157–60.
12. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333: 1154–7.
13. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifi es frequent somatic drivers. Cancer Discov 2013;3:770–81.
14. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013;3:761–9.
15. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T P, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2014 Jul 23.[Epub ahead of print].
16. TCGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519–25.
17. Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006;25:2558–64.
18. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz L A Jr, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013;110:6021–6.
19. Li R, Faden DL, Fakhry C, Langelier C, Jiao Y, Wang Y, et al. Clinical, genomic and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck. 2014 Jun 21. [Epub ahead of print].
20. Pickering CR, Zhang J, Neskey DM, Zhao M, Jasser SA, Wang J, et al. Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res 2014;20:3842–8.
21. Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS ONE 2013;8:e56823.
22. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, et al. Molecular classifi cation of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5: 489–500.
23. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identifi cation of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636–47.
24. Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Liu Q, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res 2013;73:5195–205.
25. Nogova L, Sequist LV, Cassier PA, Hidalgo M, Delord J-P, Schuler MH, et al. Targeting FGFR1-amplifi ed lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. J Clin Oncol 32:5s, 2014 (suppl; abstr 8034).
26. Bahleda R, Dienstmann R, Adamo B, Gazzah A, Infante JR, Zhong B, et al. Phase 1 study of JNJ-42756493, a pan-fi broblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 32:5s, 2014 (suppl; abstr 2501).
27. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 2014; 24: 185–99.
28. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A 2014;111:15544–9.
29. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014;506:371–5.
30. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplifi cation associates with therapeuti-cally tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
31. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplifi cation in human non-small cell lung cancer. PLoS ONE 2011;6:e20351.
32. Wolf J, LoRusso PM, Camidge RD, Pereze JM, Taberno J, Hidalgo M, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31–Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72:Abstract nr LB-122.
33. Abazeed ME, Adams DJ, Hurov KE, Tamayo P , Creighton CJ , Sonkin D, et al. Integrative radiogenomic profi ling of squamous cell lung cancer. Cancer Res 2013;73:6289–98.
34. Seiwert TY, Burtness B, Weiss J, Gluck I, Eder JP, Pai SI, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 6011).
35. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013;19:3462–73.
36. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84–8.